56232-75-8

Upstream product

• 70-23-5 ethyl Bromopyruvate 
• 513-74-6 ammonium dithiocarbamate 
• 64-17-5 ethanol 
• 89180-62-1 2-thioxo-2,3-dihydro-thiazole-4-carboxylic acid 

Downstream Products

• 105910-77-8 2-cyclohexylaminosulfanyl-thiazole-4-carboxylic acid ethyl ester 
• 91641-19-9 2-cyclohex-2-enylsulfanyl-thiazole-4-carboxylic acid ethyl ester 
• 14527-43-6 ethyl thiazole-4-carboxylate 
• 118451-99-3 ethyl 2-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-pentofuranosylthio)thiazole-4-carboxylate 
• 118451-98-2 ethyl 2-(2,3,5-tri-O-benzoyl-β-D-ribofuranosylthio)thiazole-4-carboxylate 
• 879402-32-1 (2S)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(ethoxycarbonyl)thiazol-2-ylthio]acetamide 
• 89379-90-8 ethyl 2-(chlorosulfonyl)thiazole-4-carboxylate 
• 118452-01-0 2-mercaptothiazole-4-carboxamide 
• 98996-15-7 2-Allylthio-thiazol-carbonsaeure-(4)-aethylester 
• 99970-67-9 2-(2,4-dinitro-phenylsulfanyl)-thiazole-4-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

SULFONAMIDE CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from-CH2-or-CH2-CH2;Z is seleceted from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1 -C6 straight alkyl, and C1 -C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.

MORPHOLINE COMPOUND

A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

Substituted thiazole sulfonamides as antiglaucoma agents

The present invention provides novel carbonic anhydrase inhibitors represented by the structural formula: STR1 wherein